The World Health Organization has released its first guideline on the use of Glucagon-Like Peptide-1 therapies for treating obesity, marking a major step in recognising obesity as a chronic and relapsing disease. Issued on December 1, 2025, the guideline provides conditional recommendations on medicines such as liraglutide, semaglutide and tirzepatide, which have become the first.
